BLUE OWL CAPITAL HOLDINGS LP
Q2 2024 Form 13-F

NEW YORK, NEW YORK
CIK 0001858703 · Institutional investment manager
Consolidated report · includes 10 managers since Q2 2023
$359.6M Reported Value Total
Reported value
$359.6M
Quarter over quarter
-18.6%
Holdings
41
Top-10 concentration
68.0%

Reports holdings for

  • Blue Owl Alternative Credit Advisors LLC (not a 13F filer in our records) · since Q3 2024 · declared by one filing
  • Blue Owl CLO Management I LLC (not a 13F filer in our records) · since Q1 2026 · declared by one filing
  • Blue Owl Credit Advisors LLC (not a 13F filer in our records) · since Q2 2023 · declared by one filing
  • Blue Owl Credit Private Fund Advisors LLC (not a 13F filer in our records) · since Q2 2023 · declared by one filing
  • Blue Owl Digital Infrastructure Advisors LLC (not a 13F filer in our records) · since Q2 2026 · declared by one filing
  • Blue Owl GPSC Advisors LLC (not a 13F filer in our records) · since Q2 2023 · declared by one filing
  • Blue Owl GPSC IV Advisors LLC (not a 13F filer in our records) · since Q4 2023 · declared by one filing
  • Blue Owl Healthcare Opportunities Advisors LLC (not a 13F filer in our records) · since Q1 2024 · declared by one filing
  • Blue Owl Insurance Advisors LLC (not a 13F filer in our records) · since Q3 2024 · declared by one filing
  • Blue Owl Technology Credit Advisors LLC (not a 13F filer in our records) · since Q2 2023 · declared by one filing
  • Blue Owl Healthcare Opportunities Advisors (not a 13F filer in our records) · Q4 2023 – Q4 2023 · declared by one filing
  • Dyal Advisors LLC (not a 13F filer in our records) · Q4 2021 – Q1 2023 · declared by one filing
  • Dyal IV Advisors LLC (not a 13F filer in our records) · Q4 2021 – Q1 2023 · declared by one filing
  • Owl Rock Capital Advisors LLC (not a 13F filer in our records) · Q4 2021 – Q1 2023 · declared by one filing
  • Owl Rock Capital Private Fund Advisors LLC (not a 13F filer in our records) · Q4 2021 – Q1 2023 · declared by one filing
  • Owl Rock Technology Advisors LLC (not a 13F filer in our records) · Q4 2021 – Q1 2023 · declared by one filing

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Karen Hager
Chief Compliance Officer
Q1 2024
Q3 2024
Go to latest
Loading 13F Metrics

Q2 2024 13F filing summary

Period of report June 30, 2024
Filed August 15, 2024
Form 13F-HR
Reported value $359.6M
Positions 41
Change in reported value -28.2%
New positions 11
Exited positions 16
Position turnover 47.4%
Top-10 concentration 68.0%

13F filings by quarter

Quarter Positions Value
Q2 2026 13F
Filed Aug 11, 2026
 71 $664.5M
Q1 2026 13F
Filed May 14, 2026
 74 $372.2M
Q4 2025 13F
Filed Feb 9, 2026
 78 $324.0M
Q3 2025 13F
Filed Nov 12, 2025
 72 $322.1M
Q2 2025 13F
Filed Aug 11, 2025
 72 $309.9M
Q1 2025 13F
Filed May 15, 2025
 73 $310.1M
Q4 2024 13F
Filed Feb 14, 2025
 78 $434.0M
Q3 2024 13F
Filed Nov 14, 2024
 132 $518.4M
Q2 2024 13F
Filed Aug 15, 2024
 41 $359.6M
Q1 2024 13F
Filed May 15, 2024
 44 $500.6M
Q4 2023 13F
Filed Feb 15, 2024
 42 $418.3M
Q3 2023 13F
Filed Nov 14, 2023
 15 $129.3M
Q2 2023 13F
Filed Aug 11, 2023
 16 $162.3M
Q1 2023 13F
Filed May 11, 2023
 15 $156.1M
Q4 2022 13F
Filed Feb 13, 2023
 43 $235.0M
Q3 2022 13F
Filed Nov 14, 2022
 39 $230.9M
Q2 2022 13F
Filed Aug 12, 2022
 37 $203.6M
Q1 2022 13F
Filed May 16, 2022
 31 $227.2M
Q4 2021 13F
Filed Feb 11, 2022
 25 $218.7M

Top 20 holdings · Q2 2024

# Holding Reported value % of portfolio
1 CGEM CULLINAN THERAPEUTICS INC $35.7M 9.94%
2 PLRX PLIANT THERAPEUTICS INC $32.3M 8.98%
3 OBDC BLUE OWL CAPITAL CORPORATION $31.4M 8.74%
4 KVYO KLAVIYO INC $29.8M 8.29%
5 LRMR LARIMAR THERAPEUTICS INC $28.0M 7.78%
6 ENGN ENGENE HOLDINGS INC $23.1M 6.43%
7 TRML TOURMALINE BIO INC $22.1M 6.14%
8 EVCM EVERCOMMERCE INC $18.0M 5.01%
9 SLRN ACELYRIN INC $12.9M 3.59%
10 RPTX REPARE THERAPEUTICS INC $11.1M 3.1%
11 RARE ULTRAGENYX PHARMACEUTICAL IN $11.0M 3.07%
12 CNTX CONTEXT THERAPEUTICS INC $10.3M 2.88%
13 IRON DISC MEDICINE INC $9.7M 2.7%
14 TOST TOAST INC $8.3M 2.31%
15 ETWO E2OPEN PARENT HOLDINGS INC $7.4M 2.06%
16 KROS KEROS THERAPEUTICS INC $7.2M 2.0%
17 IKNA IKENA ONCOLOGY INC $6.8M 1.88%
18 SGMT SAGIMET BIOSCIENCES INC $5.7M 1.59%
19 MLYS MINERALYS THERAPEUTICS INC $5.3M 1.47%
20 VKTX VIKING THERAPEUTICS INC $5.0M 1.4%

Values as reported on the Q2 2024 Form 13F. Every position is in the holdings table below.

Loading Activities
Loading Sector Allocation
Crunching numbers
Loading Performance
Finding Potential New Buys
Building table
Loading SEC filing data
Loading Form 4 Filings
Loading 13D/G filings